PLIANT THERAPEUTICS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
PLRX$0.80-1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $71,188 | $63,234 |
| Short-term investments | 284,536 | 431,011 |
| Prepaid expenses and other current assets (Note 5) | 6,540 | 11,257 |
| Total current assets | 362,264 | 505,502 |
| Property and equipment, net | 5,525 | 3,567 |
| Operating lease right-of-use assets | 27,243 | 1,211 |
| Restricted cash | 1,482 | 1,482 |
| Other non-current assets | 435 | 392 |
| Total assets | $396,949 | $512,154 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $5,960 | $4,531 |
| Accrued research and development | 14,363 | 12,456 |
| Accrued liabilities (Note 6) | 12,353 | 10,219 |
| Lease liabilities, current | 542 | 1,318 |
| Total current liabilities | 33,218 | 28,524 |
| Lease liabilities, non-current | 29,439 | — |
| Long-term debt (Note 7) | 30,211 | 10,054 |
| Total liabilities | 92,868 | 38,578 |
| Commitments and Contingencies (Note 14) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value 10,000,000 shares authorized at December 31, 2024 and 2023, none issued or outstanding at December 31, 2024 and 2023 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized at December 31, 2024 and 2023; and 60,860,838 and 59,921,002 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively; | 6 | 6 |
| Additional paid-in capital | 1,013,806 | 972,973 |
| Accumulated deficit | (710,052) | (499,748) |
| Accumulated other comprehensive gain | 321 | 345 |
| Total stockholders’ equity | 304,081 | 473,576 |
| Total liabilities and stockholders’ equity | $396,949 | $512,154 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.